Indian Pharmacopoeia (IP) 2022 : Addendum 2024

The Indian Pharmacopoeia plays a pivotal role in ensuring the quality and safety of drugs in the country. To fortify these standards, the Indian Pharmacopoeia Commission (IPC) has introduced the Addendum 2024 to the Indian Pharmacopoeia (IP) 2022.

Contents of Addendum 2024

The Addendum comprises a noteworthy:

• 75 new drug monographs,
• Encompassing Pharmaceuticals,
• Veterinary Pharmaceuticals,
• Phytopharmaceuticals, and
• Biotechnology-Derived Therapeutic Products.

Additionally, it introduces 9 new General Chapters and General Monographs, covering various categories such as:

• Pharmaceuticals,
• Veterinary Biological Products,
• Bacterial Endotoxins, and
• Phytopharmaceuticals.

Furthermore, a total of 220 monographs have undergone revisions, including:

• Pharmaceuticals,
• Vitamins,
• Minerals,
• Amino Acids,
• Veterinary Pharmaceuticals,
• Phytopharmaceuticals,
• Biotechnology-Derived Therapeutic Products,
• Vaccines and Immunosera for Human Use,
• Blood and Blood-Related Products, and
• Changes in titles.

Revised Monographs and General Chapters

This extensive revision involves:

• 158 Pharmaceuticals,
• 22 Vitamins, Minerals, Amino Acids, Fatty Acids etc.,
• 21 Veterinary Pharmaceuticals,
• 1 Phytopharmaceutical,
• 5 Biotechnology Derived Therapeutic Products,
• 4 Vaccines and Immunosera for Human Use,
• 6 Blood and Blood-Related Products, and
• 3 changes in titles.

Additionally, 21 General Chapters and General Monographs have undergone revisions in the IP Addendum 2024.